AI assistant
Sending…
GALECTIN THERAPEUTICS INC — Director's Dealing 2018
Feb 2, 2018
33422_dirs_2018-02-02_2dea300f-fa74-4d9d-9732-06289b58d1c2.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: GALECTIN THERAPEUTICS INC (GALT)
CIK: 0001133416
Period of Report: 2018-02-01
Reporting Person: FREEMAN KEVIN D (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2018-02-01 | Common Stock | P | 2000 | $4.0955 | Acquired | 16000 | Indirect |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 22043 | Direct |
Footnotes
F1: Includes 6,000 shares that the reporting person previously mistakenly reported as being held directly and which should have been reported as being held indirectly, by the reporting person's IRA.
More from GALECTIN THERAPEUTICS INC
Regulatory Filings
2026
May 15
Interim / Quarterly Report
2026
May 15
Capital/Financing Update
2026
Mar 31
Earnings Release
2026
Mar 31
Annual Report
2026
Mar 31
Director's Dealing
2026
Mar 17
Director's Dealing
2026
Mar 17
Board/Management Information
2026
Mar 17
Director's Dealing
2026
Feb 9
Board/Management Information
2026
Jan 21